Our platform technology

PharmaInformatic has developed a platform technology enabling the rapid development of expert systems. Our proprietary platform technology was built up with tens of millions of virtual and synthesised substances (chemical structures together with experimental or predicted data); tens of thousands of 3D-models from X-ray and NMR-experiments and a huge amount of related data from scientific literature.

Our proprietary platform technology contains:

Object oriented concepts like encapsulation, inheritance and polymorphism allow us to continuously increase the content of our technological platform. With our proprietary methods and algorithms, we can detect relationships between complex molecular patterns and specific biological activity.

Relational data

Rules, methods and algorithms

Structure activity relationships


Structure property relationships


Cluster of molecules

Molecular interaction surfaces

Molecular interaction models

chemical, pharmacological or other data and parameters

used for calculation, prediction and optimisation purposes

to detect molecular pattern, which correlate with biological activity of a substance

to detect molecular pattern, which correlate with properties of a substance

cluster of molecules based on similarity and diversity

MIS for detecting potential binding pockets on drug targets.

MIM for analysing  the interaction between molecules and a variety of biomolecules

 
The largest  knowledge base
on bioavailability worldwide.
 

An expert system for finding
suitable
drug candidates.
 

 An expert system for finding molecules with antibiotic activity.
 

 An expert system for finding molecules with antiviral activity.
 

Further Links:
PACT-F Drug discovery   Drug development Cheminformatics ADME   Pharmacokinetics  
Bioavailability Computational chemistry Molecular modeling Clinical trials Preclinical  Research
 

 
By using our platform technology, we can detect relationships between complex molecular patterns and properties of molecules.
 

IMPACT-F calculates oral bioavailability in humans much more precisely
than animal trials.


Bioavailability prediction helps to reduces failures
in clinical trials.